Heart Failure

ATLANTA — Adults with obesity, HF with preserved ejection fraction and type 2 diabetes saw marked improvements in HF symptoms and physical function with semaglutide 2.4 mg compared with placebo, despite less than typical weight loss.

ATLANTA — In the EMPACT-MI trial, empagliflozin treatment soon after an acute MI did not significantly lower risk for HF hospitalization or death from any cause compared with placebo among patients with increased risk for HF.

Childhood cancer survivors appeared significantly more likely than the general public to die after a major cardiovascular event, according to study results.

The 2024 American College of Cardiology Scientific Session will be held live in Atlanta from April 6 to 8 and virtually, with 43 late-breaking trials and featured clinical research presentations.

Adults with hyperthyroidism who undergo surgery or receive radioactive iodine therapy have a lower risk for major adverse cardiovascular events than those receiving antithyroid drugs, according to data published in JAMA Network Open.

Patients with autoimmune blistering disorders had elevated cardiovascular risks, including for atherosclerotic cardiovascular disease, heart failure, arrhythmia, venous thromboembolism and death, according to a study.

The American Cancer Society launched a national training and credentialing program designed to standardize high-quality, expert patient navigation for individuals with cancer and their caregivers.

Eko Health announced it received FDA clearance for its artificial intelligence algorithm for the detection of heart failure during routine physical exams.

Despite dapagliflozin not improving diuretic efficiency in the setting of acute HF hospitalization, it was associated with fewer diuretic doses to achieve the same weight change as usual care and shorter hospital stay, researchers reported.

Yolanda Bryce, MD, still remembers her patient’s shock.